Autopsy report · NCT02382406

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

“The study was completed. It was fully accrued.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 6 years 10 months before it stopped.
• 46 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Nisha Mohindra, MD

Sponsor type

University, hospital or other

Conditions

Non-Small Cell Lung Cancer

Interventions

Carboplatin; Nab-paclitaxel; MK-3475 (Phase I); MK-3475 (Phase II)

Participants

46

Sites

5

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.